Abeona Therapeutics, Inc. (ABEO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Oramed Pharmaceuticals, Inc.

Protalix Biotherapeutics, Inc.

Eton Pharmaceuticals, Inc.

Ocugen, Inc.

Nektar Therapeutics

Esperion Therapeutics, Inc.

ProQR Therapeutics NV

Talaris Therapeutics, Inc.

Abeona Therapeutics, Inc.

Inovio Pharmaceuticals, Inc.

Reviva Pharmaceuticals Holdings, Inc.

Why is Abeona Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Abeona Therapeutics, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Abeona Therapeutics, Inc.

-4.75%

0.31

61.36%

S&P 500

14.77%

0.81

19.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.96%

EBIT Growth (5y)

-4.49%

EBIT to Interest (avg)

-26.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.56

Sales to Capital Employed (avg)

0.18

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

76.21%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

8.33

EV to EBIT

-4.03

EV to EBITDA

-4.27

EV to Capital Employed

-12.08

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-164.21%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company

NET SALES(9M)

At USD 0.4 MM has Grown at inf%

ROCE(HY)

Highest at 48.34%

CASH AND EQV(HY)

Highest at USD 310.35 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.37 times

PRE-TAX PROFIT(Q)

Highest at USD 129.73 MM

NET PROFIT(Q)

Highest at USD 113.55 MM

EPS(Q)

Highest at USD 1.71

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -65.97 MM

INTEREST(9M)

At USD 3.04 MM has Grown at 42.38%

RAW MATERIAL COST(Y)

Grown by 11,700% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -123.36 %

OPERATING PROFIT(Q)

Lowest at USD -22.02 MM

Here's what is working for Abeona Therapeutics, Inc.

Net Sales

At USD 0.4 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 129.73 MM has Grown at 863.4%

over average net sales of the previous four periods of USD -16.99 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 113.55 MM has Grown at 768.17%

over average net sales of the previous four periods of USD -16.99 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Pre-Tax Profit

Highest at USD 129.73 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 113.55 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD 1.71

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv

Highest at USD 310.35 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 2.37 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Abeona Therapeutics, Inc.

Interest

At USD 3.04 MM has Grown at 42.38%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow

Lowest at USD -65.97 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -22.02 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Debt-Equity Ratio

Highest at -123.36 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 11,700% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Non Operating Income

Highest at USD 1.23 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income